Drug Trial Radar · NCT04381832
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Jul 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
173
Actual
Start
Jul 7, 2020
Primary completion
Aug 30, 2024
Study completion Aug 30, 2024
Sponsor
- Lead sponsor
- Arcus Biosciences, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Gilead Sciences
- First posted
- May 11, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of etrumadenant (AB928)-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).
Conditions
- Prostatic Neoplasms, Castration-Resistant
- Androgen-Resistant Prostatic Neoplasms
- Castration Resistant Prostatic Neoplasms
- Prostatic Cancer, Castration-Resistant
Interventions
EtrumadenantDrug
Etrumadenant is an A2aR and A2bR antagonist
ZimberelimabDrug
Zimberelimab is an anti-PD-1 antibody
QuemliclustatDrug
Quemliclustat is a Cluster of Differentiation (CD)73 Inhibitor.
EnzalutamideDrug
Enzalutamide is an androgen receptor inhibitor
DocetaxelDrug
Docetaxel is type of chemotherapy
SGDrug
Sacituzumab govitecan is an antibody-drug conjugate
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) in Stage 1 and 2Time frame: From study enrolment until participant discontinuation, or first occurrence of progressive disease, or death from any cause, whichever occurs first (approximately 3-5 years)
- Incidence and Severity of AEs and Serious Adverse Events (SAEs) in Stage 1Time frame: From first dose date to 90 days after the last dose (approximately 1.5 years)
Locations
19 sites in 2 countries. Site status is shown where the registry gives one.
The Oncology Institute of Hope & Innovation
Cerritos, California
The University of California, Los Angeles
Encino, California
The University of California, Irvine Medical Center
Orange, California
Florida Cancer Specialists South
Sarasota, Florida
Florida Cancer Specialists North
St. Petersburg, Florida
Florida Cancer Specialists Panhandle
Tallahassee, Florida
Florida Cancer Specialists East
West Palm Beach, Florida
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Affinity Health Hope & Healing Cancer Services
Hinsdale, Illinois
Johns Hopkins University
Baltimore, Maryland
New York University, Langone Health
New York, New York
Wilmot Cancer Institute Oncology, University of Rochester
Rochester, New York
Cleveland Clinic
Cleveland, Ohio
Tennessee Oncology - Chattanooga
Chattanooga, Tennessee
Tennessee Oncology - Nashville
Nashville, Tennessee
MD Anderson Cancer Center
Houston, Texas
Medical Oncology Associates, PS (dba Summit Cancer Centers)
Spokane, Washington
Juravinski Cancer Center
Hamilton, Ontario, Canada
Centre hospitalier de l'Université de Montréal (CHUM) Centre de Recherche
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.